Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharmaceuticals has been awarded a $3m grant from National Institutes of Health’s National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel heart attack drug candidate RGN-352.
Subscribe to our email newsletter
RGN-352 is an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tß4, for patients who have suffered an acute myocardial infarction, or AMI or heart attack.
According to RegeneRx the recent animal research suggests that this formulation may also benefit patients with multiple sclerosis and stroke.
RegeneRx Biopharmaceuticals said that the award is being issued under the American Reinvestment and Recovery Act of 2009. Furthermore, it is planning to initiate a Phase 2 clinical trial with RGN-352 later this year.
RegeneRx Biopharmaceuticals has stated that this competitive grant award will allow the company to conduct a number of key scientific activities in parallel that should facilitate the commercial development of RGN-352.
Furthermore, RegeneRx is pursuing the commercial development of peptide fragments of Tß4 for potential cosmeceutical use. RegeneRx holds over 60 worldwide patents and patent applications related to its product candidates.